A	O
microbial	O
signature	O
for	O
Crohn	B:C0010346
's	I:C0010346
disease	I:C0010346
A	O
decade	O
of	O
microbiome	O
studies	O
has	O
linked	O
IBD	O
to	O
an	O
alteration	O
in	O
the	O
gut	O
microbial	O
community	O
of	O
genetically	O
predisposed	O
subjects	O
.	O

A	O
microbial	O
signature	O
for	O
Crohn	O
's	I:C0010346
disease	I:C0010346
A	O
decade	O
of	O
microbiome	O
studies	B:C2603343
has	O
linked	O
IBD	O
to	O
an	O
alteration	O
in	O
the	O
gut	O
microbial	O
community	O
of	O
genetically	O
predisposed	O
subjects	O
.	O

A	O
microbial	O
signature	O
for	O
Crohn	O
's	I:C0010346
disease	I:C0010346
A	O
decade	O
of	O
microbiome	O
studies	O
has	O
linked	O
IBD	B:C0021390
to	O
an	O
alteration	O
in	O
the	O
gut	O
microbial	O
community	O
of	O
genetically	O
predisposed	O
subjects	O
.	O

A	O
microbial	O
signature	O
for	O
Crohn	O
's	I:C0010346
disease	I:C0010346
A	O
decade	O
of	O
microbiome	O
studies	O
has	O
linked	O
IBD	O
to	O
an	O
alteration	O
in	O
the	O
gut	B:C0699819
microbial	O
community	O
of	O
genetically	O
predisposed	O
subjects	O
.	O

A	O
microbial	O
signature	O
for	O
Crohn	O
's	I:C0010346
disease	I:C0010346
A	O
decade	O
of	O
microbiome	O
studies	O
has	O
linked	O
IBD	O
to	O
an	O
alteration	O
in	O
the	O
gut	O
microbial	O
community	O
of	O
genetically	O
predisposed	O
subjects	B:C0080105
.	O

However	O
,	O
existing	O
profiles	B:C1979963
of	O
gut	O
microbiome	O
dysbiosis	O
in	O
adult	O
IBD	O
patients	O
are	O
inconsistent	O
among	O
published	O
studies	O
,	O
and	O
did	O
not	O
allow	O
the	O
identification	O
of	O
microbial	O
signatures	O
for	O
CD	O
and	O
UC	O
.	O

However	O
,	O
existing	O
profiles	O
of	O
gut	B:C0699819
microbiome	O
dysbiosis	O
in	O
adult	O
IBD	O
patients	O
are	O
inconsistent	O
among	O
published	O
studies	O
,	O
and	O
did	O
not	O
allow	O
the	O
identification	O
of	O
microbial	O
signatures	O
for	O
CD	O
and	O
UC	O
.	O

However	O
,	O
existing	O
profiles	O
of	O
gut	O
microbiome	O
dysbiosis	B:C3658208
in	O
adult	O
IBD	O
patients	O
are	O
inconsistent	O
among	O
published	O
studies	O
,	O
and	O
did	O
not	O
allow	O
the	O
identification	O
of	O
microbial	O
signatures	O
for	O
CD	O
and	O
UC	O
.	O

However	O
,	O
existing	O
profiles	O
of	O
gut	O
microbiome	O
dysbiosis	O
in	O
adult	O
IBD	B:C0021390
patients	O
are	O
inconsistent	O
among	O
published	O
studies	O
,	O
and	O
did	O
not	O
allow	O
the	O
identification	O
of	O
microbial	O
signatures	O
for	O
CD	O
and	O
UC	O
.	O

However	O
,	O
existing	O
profiles	O
of	O
gut	O
microbiome	O
dysbiosis	O
in	O
adult	O
IBD	O
patients	O
are	O
inconsistent	O
among	O
published	O
studies	B:C2603343
,	O
and	O
did	O
not	O
allow	O
the	O
identification	O
of	O
microbial	O
signatures	O
for	O
CD	O
and	O
UC	O
.	O

However	O
,	O
existing	O
profiles	O
of	O
gut	O
microbiome	O
dysbiosis	O
in	O
adult	O
IBD	O
patients	O
are	O
inconsistent	O
among	O
published	O
studies	O
,	O
and	O
did	O
not	O
allow	O
the	O
identification	O
of	O
microbial	O
signatures	O
for	O
CD	B:C0010346
and	O
UC	O
.	O

However	O
,	O
existing	O
profiles	O
of	O
gut	O
microbiome	O
dysbiosis	O
in	O
adult	O
IBD	O
patients	O
are	O
inconsistent	O
among	O
published	O
studies	O
,	O
and	O
did	O
not	O
allow	O
the	O
identification	O
of	O
microbial	O
signatures	O
for	O
CD	O
and	O
UC	B:C0009324
.	O

Here	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
faecal	B:C0015733
microbiome	O
of	O
CD	O
with	O
patients	O
having	O
UC	O
and	O
with	O
non	O
-	O
IBD	O
subjects	O
in	O
a	O
longitudinal	O
study	I:C0023981
.	O

Here	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
faecal	O
microbiome	O
of	O
CD	B:C0010346
with	O
patients	O
having	O
UC	O
and	O
with	O
non	O
-	O
IBD	O
subjects	O
in	O
a	O
longitudinal	O
study	I:C0023981
.	O

Here	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
faecal	O
microbiome	O
of	O
CD	O
with	O
patients	O
having	O
UC	B:C0009324
and	O
with	O
non	O
-	O
IBD	O
subjects	O
in	O
a	O
longitudinal	O
study	I:C0023981
.	O

Here	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
faecal	O
microbiome	O
of	O
CD	O
with	O
patients	O
having	O
UC	O
and	O
with	O
non	O
-	O
IBD	B:C0021390
subjects	O
in	O
a	O
longitudinal	O
study	I:C0023981
.	O

Here	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
faecal	O
microbiome	O
of	O
CD	O
with	O
patients	O
having	O
UC	O
and	O
with	O
non	O
-	O
IBD	O
subjects	B:C0080105
in	O
a	O
longitudinal	O
study	I:C0023981
.	O

Here	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
faecal	O
microbiome	O
of	O
CD	O
with	O
patients	O
having	O
UC	O
and	O
with	O
non	O
-	O
IBD	O
subjects	O
in	O
a	O
longitudinal	B:C0023981
study	I:C0023981
.	O

We	O
analysed	O
a	O
cohort	B:C0599755
of	O
2045	O
non	O
-	O
IBD	O
and	O
IBD	O
faecal	O
samples	O
from	O
four	O
countries	O
(	O
Spain	O
,	O
Belgium	O
,	O
the	O
UK	O
and	O
Germany	O
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	O
of	O
115	O
million	O
sequences	O
.	O

We	O
analysed	O
a	O
cohort	O
of	O
2045	O
non	O
-	O
IBD	B:C0021390
and	O
IBD	O
faecal	O
samples	O
from	O
four	O
countries	O
(	O
Spain	O
,	O
Belgium	O
,	O
the	O
UK	O
and	O
Germany	O
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	O
of	O
115	O
million	O
sequences	O
.	O

We	O
analysed	O
a	O
cohort	O
of	O
2045	O
non	O
-	O
IBD	O
and	O
IBD	B:C0021390
faecal	O
samples	O
from	O
four	O
countries	O
(	O
Spain	O
,	O
Belgium	O
,	O
the	O
UK	O
and	O
Germany	O
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	O
of	O
115	O
million	O
sequences	O
.	O

We	O
analysed	O
a	O
cohort	O
of	O
2045	O
non	O
-	O
IBD	O
and	O
IBD	O
faecal	B:C0015733
samples	O
from	O
four	O
countries	O
(	O
Spain	O
,	O
Belgium	O
,	O
the	O
UK	O
and	O
Germany	O
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	O
of	O
115	O
million	O
sequences	O
.	O

We	O
analysed	O
a	O
cohort	O
of	O
2045	O
non	O
-	O
IBD	O
and	O
IBD	O
faecal	O
samples	O
from	O
four	O
countries	B:C0454664
(	O
Spain	O
,	O
Belgium	O
,	O
the	O
UK	O
and	O
Germany	O
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	O
of	O
115	O
million	O
sequences	O
.	O

We	O
analysed	O
a	O
cohort	O
of	O
2045	O
non	O
-	O
IBD	O
and	O
IBD	O
faecal	O
samples	O
from	O
four	O
countries	O
(	O
Spain	B:C0037747
,	O
Belgium	O
,	O
the	O
UK	O
and	O
Germany	O
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	O
of	O
115	O
million	O
sequences	O
.	O

We	O
analysed	O
a	O
cohort	O
of	O
2045	O
non	O
-	O
IBD	O
and	O
IBD	O
faecal	O
samples	O
from	O
four	O
countries	O
(	O
Spain	O
,	O
Belgium	B:C0004950
,	O
the	O
UK	O
and	O
Germany	O
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	O
of	O
115	O
million	O
sequences	O
.	O

We	O
analysed	O
a	O
cohort	O
of	O
2045	O
non	O
-	O
IBD	O
and	O
IBD	O
faecal	O
samples	O
from	O
four	O
countries	O
(	O
Spain	O
,	O
Belgium	O
,	O
the	O
UK	B:C0041700
and	O
Germany	O
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	O
of	O
115	O
million	O
sequences	O
.	O

We	O
analysed	O
a	O
cohort	O
of	O
2045	O
non	O
-	O
IBD	O
and	O
IBD	O
faecal	O
samples	O
from	O
four	O
countries	O
(	O
Spain	O
,	O
Belgium	O
,	O
the	O
UK	O
and	O
Germany	B:C0017480
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	O
of	O
115	O
million	O
sequences	O
.	O

We	O
analysed	O
a	O
cohort	O
of	O
2045	O
non	O
-	O
IBD	O
and	O
IBD	O
faecal	O
samples	O
from	O
four	O
countries	O
(	O
Spain	O
,	O
Belgium	O
,	O
the	O
UK	O
and	O
Germany	O
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	B:C0150098
of	O
115	O
million	O
sequences	O
.	O

We	O
analysed	O
a	O
cohort	O
of	O
2045	O
non	O
-	O
IBD	O
and	O
IBD	O
faecal	O
samples	O
from	O
four	O
countries	O
(	O
Spain	O
,	O
Belgium	O
,	O
the	O
UK	O
and	O
Germany	O
)	O
,	O
applied	O
a	O
16S	O
rRNA	O
sequencing	O
approach	O
and	O
analysed	O
a	O
total	O
dataset	O
of	O
115	O
million	O
sequences	B:C0162327
.	O

In	O
the	O
Spanish	B:C0086409
cohort	O
,	O
dysbiosis	O
was	O
found	O
significantly	O
greater	O
in	O
patients	O
with	O
CD	O
than	O
with	O
UC	O
,	O
as	O
shown	O
by	O
a	O
more	O
reduced	O
diversity	O
,	O
a	O
less	O
stable	O
microbial	O
community	O
and	O
eight	O
microbial	O
groups	O
were	O
proposed	O
as	O
a	O
specific	O
microbial	O
signature	O
for	O
CD	O
.	O

In	O
the	O
Spanish	O
cohort	B:C0599755
,	O
dysbiosis	O
was	O
found	O
significantly	O
greater	O
in	O
patients	O
with	O
CD	O
than	O
with	O
UC	O
,	O
as	O
shown	O
by	O
a	O
more	O
reduced	O
diversity	O
,	O
a	O
less	O
stable	O
microbial	O
community	O
and	O
eight	O
microbial	O
groups	O
were	O
proposed	O
as	O
a	O
specific	O
microbial	O
signature	O
for	O
CD	O
.	O

In	O
the	O
Spanish	O
cohort	O
,	O
dysbiosis	B:C3658208
was	O
found	O
significantly	O
greater	O
in	O
patients	O
with	O
CD	O
than	O
with	O
UC	O
,	O
as	O
shown	O
by	O
a	O
more	O
reduced	O
diversity	O
,	O
a	O
less	O
stable	O
microbial	O
community	O
and	O
eight	O
microbial	O
groups	O
were	O
proposed	O
as	O
a	O
specific	O
microbial	O
signature	O
for	O
CD	O
.	O

In	O
the	O
Spanish	O
cohort	O
,	O
dysbiosis	O
was	O
found	O
significantly	O
greater	O
in	O
patients	O
with	O
CD	B:C0010346
than	O
with	O
UC	O
,	O
as	O
shown	O
by	O
a	O
more	O
reduced	O
diversity	O
,	O
a	O
less	O
stable	O
microbial	O
community	O
and	O
eight	O
microbial	O
groups	O
were	O
proposed	O
as	O
a	O
specific	O
microbial	O
signature	O
for	O
CD	O
.	O

In	O
the	O
Spanish	O
cohort	O
,	O
dysbiosis	O
was	O
found	O
significantly	O
greater	O
in	O
patients	O
with	O
CD	O
than	O
with	O
UC	B:C0009324
,	O
as	O
shown	O
by	O
a	O
more	O
reduced	O
diversity	O
,	O
a	O
less	O
stable	O
microbial	O
community	O
and	O
eight	O
microbial	O
groups	O
were	O
proposed	O
as	O
a	O
specific	O
microbial	O
signature	O
for	O
CD	O
.	O

In	O
the	O
Spanish	O
cohort	O
,	O
dysbiosis	O
was	O
found	O
significantly	O
greater	O
in	O
patients	O
with	O
CD	O
than	O
with	O
UC	O
,	O
as	O
shown	O
by	O
a	O
more	O
reduced	O
diversity	O
,	O
a	O
less	O
stable	O
microbial	O
community	O
and	O
eight	O
microbial	O
groups	O
were	O
proposed	O
as	O
a	O
specific	O
microbial	O
signature	O
for	O
CD	B:C0010346
.	O

Tested	O
against	O
the	O
whole	O
cohort	B:C0599755
,	O
the	O
signature	O
achieved	O
an	O
overall	O
sensitivity	O
of	O
80	O
%	O
and	O
a	O
specificity	O
of	O
94	O
%	O
,	O
94	O
%	O
,	O
89	O
%	O
and	O
91	O
%	O
for	O
the	O
detection	O
of	O
CD	O
versus	O
healthy	O
controls	O
,	O
patients	O
with	O
anorexia	O
,	O
IBS	O
and	O
UC	O
,	O
respectively	O
.	O

Tested	O
against	O
the	O
whole	O
cohort	O
,	O
the	O
signature	O
achieved	O
an	O
overall	O
sensitivity	O
of	O
80	O
%	O
and	O
a	O
specificity	O
of	O
94	O
%	O
,	O
94	O
%	O
,	O
89	O
%	O
and	O
91	O
%	O
for	O
the	O
detection	B:C1511790
of	O
CD	O
versus	O
healthy	O
controls	O
,	O
patients	O
with	O
anorexia	O
,	O
IBS	O
and	O
UC	O
,	O
respectively	O
.	O

Tested	O
against	O
the	O
whole	O
cohort	O
,	O
the	O
signature	O
achieved	O
an	O
overall	O
sensitivity	O
of	O
80	O
%	O
and	O
a	O
specificity	O
of	O
94	O
%	O
,	O
94	O
%	O
,	O
89	O
%	O
and	O
91	O
%	O
for	O
the	O
detection	O
of	O
CD	B:C0010346
versus	O
healthy	O
controls	O
,	O
patients	O
with	O
anorexia	O
,	O
IBS	O
and	O
UC	O
,	O
respectively	O
.	O

Tested	O
against	O
the	O
whole	O
cohort	O
,	O
the	O
signature	O
achieved	O
an	O
overall	O
sensitivity	O
of	O
80	O
%	O
and	O
a	O
specificity	O
of	O
94	O
%	O
,	O
94	O
%	O
,	O
89	O
%	O
and	O
91	O
%	O
for	O
the	O
detection	O
of	O
CD	O
versus	O
healthy	O
controls	O
,	O
patients	O
with	O
anorexia	B:C0003123
,	O
IBS	O
and	O
UC	O
,	O
respectively	O
.	O

Tested	O
against	O
the	O
whole	O
cohort	O
,	O
the	O
signature	O
achieved	O
an	O
overall	O
sensitivity	O
of	O
80	O
%	O
and	O
a	O
specificity	O
of	O
94	O
%	O
,	O
94	O
%	O
,	O
89	O
%	O
and	O
91	O
%	O
for	O
the	O
detection	O
of	O
CD	O
versus	O
healthy	O
controls	O
,	O
patients	O
with	O
anorexia	O
,	O
IBS	B:C0022104
and	O
UC	O
,	O
respectively	O
.	O

Tested	O
against	O
the	O
whole	O
cohort	O
,	O
the	O
signature	O
achieved	O
an	O
overall	O
sensitivity	O
of	O
80	O
%	O
and	O
a	O
specificity	O
of	O
94	O
%	O
,	O
94	O
%	O
,	O
89	O
%	O
and	O
91	O
%	O
for	O
the	O
detection	O
of	O
CD	O
versus	O
healthy	O
controls	O
,	O
patients	O
with	O
anorexia	O
,	O
IBS	O
and	O
UC	B:C0009324
,	O
respectively	O
.	O

Although	O
UC	B:C0009324
and	O
CD	O
share	O
many	O
epidemiologic	O
,	O
immunologic	O
,	O
therapeutic	O
and	O
clinical	O
features	O
,	O
our	O
results	O
showed	O
that	O
they	O
are	O
two	O
distinct	O
subtypes	O
of	O
IBD	O
at	O
the	O
microbiome	O
level	O
.	O

Although	O
UC	O
and	O
CD	B:C0010346
share	O
many	O
epidemiologic	O
,	O
immunologic	O
,	O
therapeutic	O
and	O
clinical	O
features	O
,	O
our	O
results	O
showed	O
that	O
they	O
are	O
two	O
distinct	O
subtypes	O
of	O
IBD	O
at	O
the	O
microbiome	O
level	O
.	O

Although	O
UC	O
and	O
CD	O
share	O
many	O
epidemiologic	O
,	O
immunologic	O
,	O
therapeutic	O
and	O
clinical	O
features	O
,	O
our	O
results	O
showed	O
that	O
they	O
are	O
two	O
distinct	O
subtypes	B:C0449560
of	O
IBD	O
at	O
the	O
microbiome	O
level	O
.	O

Although	O
UC	O
and	O
CD	O
share	O
many	O
epidemiologic	O
,	O
immunologic	O
,	O
therapeutic	O
and	O
clinical	O
features	O
,	O
our	O
results	O
showed	O
that	O
they	O
are	O
two	O
distinct	O
subtypes	O
of	O
IBD	B:C0021390
at	O
the	O
microbiome	O
level	O
.	O

For	O
the	O
first	O
time	O
,	O
we	O
are	O
proposing	O
microbiomarkers	B:C0005516
to	O
discriminate	O
between	O
CD	O
and	O
non	O
-	O
CD	O
independently	O
of	O
geographical	O
regions	I:C0017446
.	O

For	O
the	O
first	O
time	O
,	O
we	O
are	O
proposing	O
microbiomarkers	O
to	O
discriminate	O
between	O
CD	B:C0010346
and	O
non	O
-	O
CD	O
independently	O
of	O
geographical	O
regions	I:C0017446
.	O

For	O
the	O
first	O
time	O
,	O
we	O
are	O
proposing	O
microbiomarkers	O
to	O
discriminate	O
between	O
CD	O
and	O
non	O
-	O
CD	B:C0010346
independently	O
of	O
geographical	O
regions	I:C0017446
.	O

For	O
the	O
first	O
time	O
,	O
we	O
are	O
proposing	O
microbiomarkers	O
to	O
discriminate	O
between	O
CD	O
and	O
non	O
-	O
CD	O
independently	O
of	O
geographical	B:C0017446
regions	I:C0017446
.	O

